In this Issue:
Adalimumab pharmacokinetics in CD
Opioid use in IBD
Hospital resource use with infliximab vs. cyclosporin for severe UC
Vedolizumab induction for CD failing anti-TNF treatment
Cancer risk with immunosuppressants in IBD and previous cancer
Features shared by CD patients and their siblings
Treating bone loss in osteopenic CD
Infliximab concentration and CRP associated with sustained response
Capsule endoscopy findings correlate with calprotectin/CRP in suspected small-bowel CD
Mesalazine dose escalation reduces calprotectin in quiescent UC
Please login below to download this issue (PDF)